Why the study?
Does prophylactic losartan prevent right ventricular hypertrophy and alter cardiac ACE activity in a rat model of monocrotaline-induced pulmonary hypertension?
Does prophylactic losartan prevent right ventricular hypertrophy and alter cardiac ACE activity in a rat model of monocrotaline-induced pulmonary hypertension?
In a rat model of pulmonary hypertension, prophylactic losartan failed to prevent right ventricular hypertrophy but significantly increased right ventricular ACE activity.
Losartan fails to prevent right ventricular hypertrophy in this rat model; leaves open the role of upregulated ACE activity in pulmonary hypertension progression.
The aim of this study was to investigate the effect of prophylactic treatment with the angiotensin type 1 (AT1) receptor antagonist losartan on right ventricular hypertrophy and cardiac angiotensin 1-converting enzyme (ACE) activity in a rat model of monocrotaline-induced pulmonary hypertension. Losartan failed to prevent either pulmonary hypertension or right ventricular hypertrophy. Right ventricular ACE in untreated pulmonary hypertensive rats did not differ from control rats. Losartan treatment in pulmonary hypertensive rats caused a significant 2-fold increase of ACE activity in the hypertrophied right (p < 0.005) but not in the left ventricle. Thus, cardiac ACE activity is not stimulated in rats with monocrotaline-induced right ventricular hypertrophy. Prophylactic losartan treatment in this model of progressive pulmonary hypertension failed to prevent or reduce the increase in ventricular afterload. The relevance of the increase in right ventricular ACE activity during pulmonary hypertension after losartan treatment is unknown and needs to be evaluated in further studies.
No takes yet. Share an insight, caveat, or question.
Kreutz et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: